Business Wire

PAX Unveils Long-Anticipated PAX FOUR, Its Most Powerful Dry Herb Vaporizer Yet

3.3.2026 14:00:00 CET | Business Wire | Press Release

Share

Nearly two decades after defining the category, PAX today announced the launch of PAX FOUR, the most powerful dry herb vaporizer in the company’s history. Built for consumers who want dense vapor and immediate impact without combustion, PAX FOUR delivers smoking-level intensity you can see and feel in a sleek, precision-engineered device.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260303740648/en/

PAX FOUR, the most powerful dry herb vaporizer in the company’s history.

The cannabis vaporization category continues to grow as consumers shift away from smoking and combustion, yet many remain loyal to traditional smoking methods, often citing weak vapor, lack of intensity, and inconsistent performance from existing devices. PAX FOUR was engineered to change that — producing larger clouds and consistent performance while preserving PAX’s signature portability and design.

“PAX FOUR is all about power,” said Chris Ahern, CEO of PAX. “There’s a significant consumer segment out there who want to feel a stronger, more well-rounded impact — whether it’s a single hit or a full session — without sacrificing flavor or ease of use. PAX FOUR delivers dense vapor, fast onset and real intensity in a way that’s controlled, consistent and true to the flower-forward quality PAX is known for.”

At the core of PAX FOUR is a redesigned high-output hybrid heating system that produces 50% more vapor and faster heat-up than any previous PAX dry herb device. Four preset heat modes with patented temperature control allow users to tailor intensity — from quick, high-impact sessions to longer, more sustained experiences — without compromising flavor or cannabinoid performance. The device also features haptic feedback controls, a redesigned oven for easier loading and cleaning, fast USB-C charging, and up to 50 minutes of battery life, all in a design that is 40% smaller and 75% lighter than competing vaporizers.

Unlike smoking, PAX FOUR heats cannabis flower rather than burning it, avoiding harmful byproducts created by combustion while still delivering the visible vapor and potency consumers expect. The result is a cleaner, smoother experience without sacrificing power.

PAX FOUR is available in Onyx and Greenstone colorways beginning March 3, 2026 on pax.com and at select retailers globally for $250 MSRP. FOUR joins FLOW and MINI to complete PAX’s dry herb lineup, offering refined options at multiple price points for consumers whether the priority is flavor, power, or simplicity.

PAX is a leading global cannabis brand on a mission to enhance people’s lives, honoring the power of the plant through pioneering innovation, peerless quality and premium design. For nearly two decades, PAX has delivered high-performance products — crafted for precision, purity and consistency — that are trusted by millions. PAX is committed to making a positive impact and is certified Plastic Negative across all product lines by rePurpose Global, removing twice as much plastic from nature as is used in PAX products.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260303740648/en/

Contacts

MEDIA CONTACT:
press@pax.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press Release

Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press Release

Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press Release

Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development

Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press Release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press Release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye